Anagrelide is a prescription platelet-lowering medication that must be used precisely under the guidance of a physician.

I. Dosage and Administration

1. Adult Starting Dose

(1) The recommended starting dose is 0.5 mg four times daily or 1 mg twice daily.

(2) Maintain the starting dose for at least one week before adjusting.

2. Pediatric Starting Dose (Aged 7 Years and Older)

(1) The recommended starting dose is 0.5 mg once daily.

(2) No data are available for use in children under 7 years of age.

3. Dose Titration Schedule

(1) The weekly dose increment must not exceed 0.5 mg/day. The maximum dose is 2.5 mg per single dose and 10 mg per day.

(2) Most patients achieve satisfactory efficacy at a daily dose of 1.5 to 3.0 mg.

4. Dose Adjustment for Hepatic Impairment

(1) For patients with moderate hepatic impairment (Child-Pugh score 7–9), start at 0.5 mg/day. Dose may be increased after one week, with weekly increments not exceeding 0.5 mg/day.

(2) Avoid use in patients with severe hepatic impairment.

II. Precautions for Use

1. Cardiovascular Risks

(1) An electrocardiogram (ECG) must be performed before treatment to assess baseline cardiovascular status.

(2) This drug may cause QTc interval prolongation and tachycardia.

(3) Contraindicated in patients with congenital long QT syndrome, a history of acquired QTc prolongation, or hypokalemia.

(4) Use in patients with heart failure only if benefits outweigh risks.

2. Bleeding Risks

(1) Concomitant use with aspirin significantly increases the risk of major bleeding eventsFDA Access Data.

(2) Avoid concurrent use with anticoagulants, NSAIDs, or other antiplatelet agents during treatment. Seek immediate medical attention if gingival bleeding, skin ecchymosis, melena, or hematemesis occursFDA Access Data.

3. Pulmonary Risks

(1) Evaluate for cardiopulmonary disease before and during treatment.

(2) If progressive dyspnea with pulmonary infiltrates develops, suspect interstitial lung disease. Discontinue the drug immediately and perform a pulmonary evaluation.

4. Liver Function Monitoring

Drug exposure in patients with moderate hepatic impairment is approximately 8-fold higher than in healthy individuals; close monitoring for cardiovascular events is required. Regularly recheck liver function during treatment.

5. Lactation Contraindication

Breastfeeding is not recommended during treatment and for one week after the last dose. Animal studies indicate the drug is excreted in milk.

6. Effects on Fertility

Animal studies suggest anagrelide may impair female fertility; women of childbearing potential should be informed.

III. Healthy Lifestyle Recommendations

1. Low-Sodium Diet

(1) The incidence of edema is as high as 21%, with peripheral edema at 9%.

(2) Restrict sodium intake to reduce fluid retention.

2. Adequate Hydration

(1) The incidence of diarrhea is 26%, and nausea is 17%.

(2) Replenish fluids and electrolytes during diarrhea to prevent dehydrationFDA Access Data.

3. Take with Meals

(1) Taking with meals may reduce gastrointestinal irritation.

(2) Although food reduces peak plasma concentration by 14%, total exposure increases by 20%, which does not affect efficacy.

4. Avoid Driving

(1) The incidence of dizziness is 15%, and paresthesia is 6%.

(2) Dizziness may occur early in treatment; avoid driving or operating dangerous machinery.

5. Monitor Weight

Weigh yourself at a fixed time daily. Notify your doctor promptly if you experience rapid weight gain or lower extremity swelling in a short period.

6. Watch for Bleeding Signs

Gingival bleeding during brushing, extensive bruising after minor trauma, black or bloody stools are warning signs—seek immediate medical attentionFDA Access Data.

7. Regular Follow-Ups

(1) Adhere to the doctor’s instructions for regular monitoring of platelets, liver and kidney function, and ECG. Do not adjust the dose or discontinue treatment on your own.

(2) Platelet counts may rebound after discontinuation; close monitoring is required.